Auration Biotech

Executive Summary

Auration Biotech is a privately held biotechnology company headquartered in Cambridge, MA, founded in 2014 with a mission to develop novel therapeutics for ear, nose, and throat (ENT) diseases. Its lead program, AU-935 (HB-EGF), targets non-surgical repair of the tympanic membrane, addressing a significant unmet need in otology. The company is led by experienced management including founder Benjamin F. McGraw, III (Executive Chairman) and a scientific advisory board chaired by Dr. Peter Santa Maria. Auration operates in the biologics space and appears to be in the preclinical or early clinical stage, given the absence of disclosed funding rounds or clinical trial data. The company's focus on a single asset in a niche indication positions it for potential development efficiency but also carries high risk typical of early-stage biotech. While no recent news or pipeline updates are available, the company's profile suggests a disciplined approach to advancing its lead candidate toward the clinic.

Upcoming Catalysts (preview)

• Q4 2026Clinical trial initiation for AU-93520% success
• Q3 2026Series A or seed funding round40% success
• Q1 2027Partnership or licensing deal for AU-93525% success